Advertisement

Midterm Outcomes of Tildrakizumab on Psoriasis in PsA

Interim results of an ongoing randomized, double-blind, multidose, placebo-controlled, phase IIb study on the efficacy of tildrakizumab on psoriasis treatment in patients with psoriatic...

Romosozumab versus Placebo: A Comparison in Varying Levels of Kidney Disease

A post-hoc analysis of the FRAME study analyzed safety and efficacy outcomes of romosozumab compared with placebo among postmenopausal women with mild-to-moderate kidney disease....

Which RA Patients Have the Greatest Risk of Flares after DMARD Tapering?

A study presented at the ACR/ARP Annual Meeting evaluated whether high levels of calprotectin were indicative of flare after disease-modifying antirheumatic (DMARD) tapering in...

Rheumatic Risk Factors Vary by Disease

A series of case-control studies presented at the ACR/ARP Annual Meeting highlighted shared and different risk factors for psoriatic arthritis (PsA), psoriasis, ankylosing spondylitis...
Advertisement